An antibody-based drug derived from the blood of an early U.S. survivor of Covid-19 reduced the rate of hospitalization compared with placebo in a new study of people recently diagnosed with the disease, said Eli Lilly & Co., one of the drug’s developers.
Indianapolis-based Lilly said Wednesday that the interim results reinforced the potential of the drug to help Covid-19 patients, and the company will discuss with regulators whether there is enough evidence to support the therapy’s authorization for emergency use during…
Real Life. Real News. Real Voices
Help us tell more of the stories that matterBecome a founding member
Subscribe to the newsletter news
We hate SPAM and promise to keep your email address safe